Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, China.
Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Aging (Albany NY). 2023 Sep 8;15(17):8930-8947. doi: 10.18632/aging.205008.
Hepatocellular carcinoma (HCC) is the most common subtype, accounting for about 90% of all primary liver cancers. The liver is rich in a large number of immune cells, thus forming a special immune microenvironment, which plays a key role in the occurrence and development of hepatocellular carcinoma. Nowadays, tumor immunotherapy has become one of the most promising cancer treatment methods. Immune checkpoint inhibitors (ICIs) combined with VEGF inhibitors are listed as first-line treatment options for advanced HCC. Therefore, the search for a potential biomarker to predict the response to immunotherapy in HCC patients is urgently needed. The G protein-coupled receptor 55 (), a lysophosphatidylinositol (LPI) receptor, has recently emerged as a potential new target for anti-tumor therapy. Previous studies have found that is highly expressed in breast cancer, pancreatic cancer, skin cancer and cholangiocarcinoma, and is involved in tumor proliferation and migration. However, the role and mechanism of in HCC has not been elucidated. Therefore, this article discusses the clinical significance of in HCC and its correlation with the immune response of HCC patients, so as to provide theoretical basis for improving the prognosis of HCC.
肝细胞癌（HCC）是最常见的亚型，约占所有原发性肝癌的 90%。肝脏富含大量免疫细胞，从而形成特殊的免疫微环境，在肝癌的发生和发展中起着关键作用。如今，肿瘤免疫疗法已成为最有前途的癌症治疗方法之一。免疫检查点抑制剂（ICI）联合血管内皮生长因子抑制剂被列为晚期 HCC 的一线治疗选择。因此，迫切需要寻找一种潜在的生物标志物来预测 HCC 患者对免疫治疗的反应。G 蛋白偶联受体 55（）是一种溶血磷脂酰肌醇（LPI）受体，最近已成为抗肿瘤治疗的潜在新靶点。先前的研究发现，在乳腺癌、胰腺癌、皮肤癌和胆管癌中高度表达，并参与肿瘤的增殖和迁移。然而，在 HCC 中尚未阐明的作用和机制。因此，本文讨论了在 HCC 中的临床意义及其与 HCC 患者免疫反应的相关性，以期为改善 HCC 的预后提供理论依据。
